LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2, diversifying revenue beyond GLP-1. However, the stock trades at a premium 26.3x forward earnings amid intensifying competition from Novo Nordisk and smaller biotechs in the oral GLP-1 market. Analysts recommend existing investors hold while new investors consider accumulating on market corrections.